Chad Quist, PA
Surgical · Des Moines, IANPI 1609836444
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,893 of the $40,138 with a category attached, or 86.9%. AbbVie accounts for 92.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $15,259 and has fallen 91.8% since, to $1,256 in 2025. Among surgical clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $152.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$37K
- Teva Pharmaceuticals USA, Inc.$664
- Livanova USA, Inc.$656
- SK Life Science, Inc.$432
- UCB, Inc.$251
- Lilly USA, LLC$232
- plus $841 from 12 others
What the payments were for
- Speaking & faculty fees$34,89387%
- Food & beverage$4,78312%
- Education$4631%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 133 | $37,062 |
| Teva Pharmaceuticals USA, Inc. | 22 | $664 |
| Livanova USA, Inc. | 32 | $656 |
| SK Life Science, Inc. | 15 | $432 |
| UCB, Inc. | 14 | $251 |
| Lilly USA, LLC | 14 | $232 |
| Lundbeck LLC | 5 | $142 |
| Axsome Therapeutics, Inc. | 1 | $120 |
| Pfizer | 6 | $91 |
| Johnson & Johnson | 1 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $82 |
| Novartis | 4 | $75 |
| Jazz Pharmaceuticals Inc. | 3 | $70 |
| Neurelis, Inc. | 2 | $64 |
| Amgen | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,138 in reported general payments places this provider in the 95th percentile of 49 surgical providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 18 | $158,422 |
| QuliptaAtogepant | 75 | $102,513 |
| Emgality PenGalcanezumab-Gnlm | 127 | $98,386 |
| Nurtec OdtRimegepant Sulfate | 51 | $88,312 |
| Dimethyl Fumarate | 24 | $59,532 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 34 | $29,214 |
| AptiomEslicarbazepine Acetate | 12 | $28,618 |
| UbrelvyUbrogepant | 25 | $27,239 |
| BriviactBrivaracetam | 12 | $17,340 |
| Emgality SyringeGalcanezumab-Gnlm | 17 | $15,222 |
| XcopriCenobamate | 11 | $12,755 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $12,068 |
| Lacosamide | 99 | $8,593 |
| Levetiracetam | 194 | $6,501 |
| Topiramate | 286 | $3,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $664 | $158,42218 claims |
| AbbVieQulipta, Ubrelvy | $37,062 | $129,752100 claims |
| PfizerNurtec Odt, Dilantin | $91 | $90,55262 claims |
| UCB, Inc.Briviact | $251 | $17,34012 claims |
| SK Life Science, Inc.Xcopri | $432 | $12,75511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 surgical providers in Iowa.
Other surgical in Des Moines
- Dudley PhippsDes Moines$173K
- Joel RandDes Moines$4K
- Robey OrewilerDes Moines$1K
- Jennifer StandiferDes Moines$205
- Kaylene RogersDes Moines$95
- Eric HedrickDes Moines$57
- Laura SchiltzDes Moines$46
- Gary AldrichCedar Rapids$10K
- Jordan ReinerClive$5K
- Lauren CooperIowa City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.